The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials
Open accessAbstract
OBJECTIVES: To assess the benefits and harms of reboxetine versus placebo or selective serotonin reuptake inhibitors (SSRIs) in the acute treatment of depression, and to measure the impact of potential publication bias in trials of reboxetine. DESIGN: Systematic review and meta-analysis including unpublished data. DATA SOURCES: Bibliographic databases (Medline, Embase, PsycINFO, BIOSIS, and Cochrane Library), clinical trial registries, trial results databases, and regulatory authority websites up until February 2009, as well as unpublished data from the manufacturer of reboxetine (Pfizer, Berlin). ELIGIBILITY CRITERIA: Double blind, randomised, controlled trials of acute treatment (six weeks or more) with reboxetine versus placebo or SSRIs in adults with major depression. OUTCOME MEASURES: Remission and response rates (benefit outcomes), as well as rates of patients with at least one adverse event and withdrawals owing to adverse events (harm outcomes). DATA EXTRACTION AND DATA SYNTHESIS: The procedures for data extraction and assessment of risk of bias were always conducted by one person and checked by another. If feasible, data were pooled by meta-analyses (random effects model). Publication bias was measured by comparing results of published and unpublished trials. RESULTS: We analysed 13 acute treatment trials that were placebo controlled, SSRI controlled, or both, which included 4098 patients. Data on 74% (3033/4098) of these patients were unpublished. In the reboxetine versus placebo comparison, no significant differences in remission rates were shown (odds ratio 1.17, 95% confidence interval 0.91 to 1.51; P=0.216). Substantial heterogeneity (I(2)=67.3%) was shown in the meta-analysis of the eight trials that investigated response rates for reboxetine versus placebo. A sensitivity analysis that excluded a small inpatient trial showed no significant difference in response rates between patients receiving reboxetine and those receiving placebo (OR 1.24, 95% CI 0.98 to 1.56; P=0.071; I(2)=42.1%). Reboxetine was inferior to SSRIs (fluoxetine, paroxetine, and citalopram) for remission rates (OR 0.80, 95% CI 0.67 to 0.96; P=0.015) and response rates (OR 0.80, 95% CI 0.67 to 0.95; P=0.01). Reboxetine was inferior to placebo for both harm outcomes (P<0.001 for both), and to fluoxetine for withdrawals owing to adverse events (OR 1.79, 95% CI 1.06 to 3.05; P=0.031). Published data overestimated the benefit of reboxetine versus placebo by up to 115% and reboxetine versus SSRIs by up to 23%, and also underestimated harm. CONCLUSIONS: Reboxetine is, overall, an ineffective and potentially harmful antidepressant. Published evidence is affected by publication bias, underlining the urgent need for mandatory publication of trial data.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework
(2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.113989 · Cited by 6,762
Abraham, J. (2010) · Handbook of Transnational Economic Governance Regimes · doi:10.1163/ej.9789004163300.i-1081.897 · Cited by 2,582
Kirsch, I., Deacon, B. J., Huedo-Medina, T. B., Scoboria, A., Moore, T. J., & Johnson, B. T. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050045 · Cited by 2,442
Selective publication of antidepressant trials and its influence on apparent efficacy
Turner, E. H., Matthews, A. M., Linardatos, E., Tell, R. A., & Rosenthal, R. (2008) · New England Journal of Medicine · doi:10.1056/nejmsa065779 · Cited by 2,435
Chan, A.-W., Hróbjartsson, A., Haahr, M. T., Gøtzsche, P. C., & Altman, D. G. (2004) · JAMA · doi:10.1001/jama.291.20.2457 · Cited by 1,845
Cipriani, A., Furukawa, T. A., Salanti, G., Geddes, J. R., Higgins, J. P., Churchill, R., Watanabe, N., Nakagawa, A., Omori, I. M., McGuire, H., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60046-5 · Cited by 1,654
Advanced methods in meta‐analysis: multivariate approach and meta‐regression
van Houwelingen, H. C., Arends, L. R., & Stijnen, T. (2002) · Statistics in Medicine · doi:10.1002/sim.1040 · Cited by 1,580
Systematic Review of the Empirical Evidence of Study Publication Bias and Outcome Reporting Bias
Dwan, K., Altman, D. G., Arnaiz, J. A., Bloom, J., Chan, A.-W., Cronin, E., Decullier, E., Easterbrook, P. J., Von Elm, E., Gamble, C., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003081 · Cited by 1,546
Whittington, C. J., Kendall, T., Fonagy, P., Cottrell, D., Cotgrove, A., & Boddington, E. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16043-1 · Cited by 1,058
Dissemination and publication of research findings: an updated review of related biases
Song, F., Parekh, Hooper, L., Loke, Y., Ryder, J., Sutton, A., Hing, C., Kwok, C., Pang, C., & Harvey, I. (2010) · Health Technology Assessment · doi:10.3310/hta14080 · Cited by 1,039
Sterling, T. D. (1959) · Journal of the American Statistical Association · doi:10.1080/01621459.1959.10501497 · Cited by 964
The National Collaborating Centre for Mental Health
Kendall, T., & Pilling, S. (2004) · UCL Discovery (University College London) · Cited by 840
Publication bias: evidence of delayed publication in a cohort study of clinical research projects
Stern, J. M., & Simes, R. J. (1997) · BMJ · doi:10.1136/bmj.315.7109.640 · Cited by 818
Publication bias: the case for an international registry of clinical trials.
Simes, R. J. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.10.1529 · Cited by 747
Melander, H., Ahlqvist-Rastad, J., Meijer, G., & Beermann, B. (2003) · BMJ · doi:10.1136/bmj.326.7400.1171 · Cited by 635
Publication and Related Biases
Song, F., Eastwood, A., Gilbody, S., Duley, L., & Sutton, A. (2001) · The Advanced Handbook of Methods in Evidence Based Healthcare · doi:10.4135/9781848608344.n21 · Cited by 455
Reporting bias in medical research - a narrative review
McGauran, N., Wieseler, B., Kreis, J., Schüler, Y.-B., Kölsch, H., & Kaiser, T. (2010) · Trials · doi:10.1186/1745-6215-11-37 · Cited by 452
Self-citationOutcome Reporting in Industry-Sponsored Trials of Gabapentin for Off-Label Use
Vedula, S. S., Bero, L., Scherer, R. W., & Dickersin, K. (2009) · New England Journal of Medicine · doi:10.1056/nejmsa0906126 · Cited by 361
Perlis, R. H., Perlis, C. S., Wu, Y., Hwang, C., Joseph, M., & Nierenberg, A. A. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.10.1957 · Cited by 318
Frances, R. J. (2007) · Yearbook of Psychiatry and Applied Mental Health · doi:10.1016/s0084-3970(08)70411-0 · Cited by 220
Hajós, M., Fleishaker, J. C., Filipiak‐Reisner, J. K., Brown, M. T., & Wong, E. H. F. (2004) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2004.tb00002.x · Cited by 218
Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy
THIERS, B. H. (2009) · Yearbook of Dermatology and Dermatologic Surgery · doi:10.1016/s0093-3619(08)79042-7 · Cited by 157
Berlanga, C., & Flores‐Ramos, M. (2006) · Journal of Affective Disorders · doi:10.1016/j.jad.2006.04.029 · Cited by 149
Reboxetine: a double-blind comparison with fluoxetine in major depressive disorder
Massana, J., llerb, H.-J. M., Burrows, G. D., & Montenegro, R. M. (1999) · International Clinical Psychopharmacology · doi:10.1097/00004850-199903000-00003 · Cited by 117
Reboxetine versus paroxetine versus placebo: effects on cognitive functioning in depressed patients
Ferguson, J. M., Wesnes, K. A., & Schwartz, G. E. (2003) · International Clinical Psychopharmacology · doi:10.1097/00004850-200301000-00002 · Cited by 112
Clinical trials and drug promotion: Selective reporting of study 329
Jureidini, J. N., McHenry, L. B., & Mansfield, P. R. (2008) · International Journal of Risk & Safety in Medicine · doi:10.3233/jrs-2008-0426 · Cited by 98
Bech, P., Tanghøj, P., Andersen, H. F., & Overø, K. F. (2002) · Psychopharmacology · doi:10.1007/s00213-002-1147-6 · Cited by 91
Clayton, A. H., Zajecka, J., Ferguson, J. M., Filipiak‐Reisner, J. K., Brown, M. T., & Schwartz, G. E. (2003) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000066456.73432.09 · Cited by 89
Dubini, A., Bosc, M., & Polin, V. (1997) · PubMed · Cited by 88
Do noradrenaline and serotonin differentially affect social motivation and behaviour?
Dubini, A., Bosc, M., & Polin, V. (1997) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(97)00419-7 · Cited by 85
Baldwin, D. S., Bridgman, K. M., & Buis, C. (2005) · Journal of Psychopharmacology · doi:10.1177/0269881105056666 · Cited by 74
Papakostas, G. I., Nelson, J. C., Kasper, S., & Möller, H.-J. (2008) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2007.07.005 · Cited by 73
Versiani, M., Amin, M., & Chouinard, G. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200002000-00006 · Cited by 70
Influence of drug company authorship and sponsorship on drug trial outcomes
Tungaraza, T. E., & Poole, R. (2007) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.106.024547 · Cited by 66
Relationship between drug company funding and outcomes of clinical psychiatric research
KELLY, R. E., Cohen, L. J., Semple, R. J., Bialer, P. A., Lau, A., BODENHEIMER, A., NEUSTADTER, E., Barenboim, A., & GALYNKER, I. I. (2006) · Psychological Medicine · doi:10.1017/s0033291706008567 · Cited by 64
"Wish Bias" in Antidepressant Drug Trials?
Barbui, C., Cipriani, A., Brambilla, P., & Hotopf, M. H. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000115665.45074.0d · Cited by 63
Community provision of hearing aids and related audiology services.
Reeves, Alborz, Hickson, Bamford, & Gosden (2000) · Health Technology Assessment · doi:10.3310/hta4040 · Cited by 60
Andreoli, V. M., Caillard, V., Deo, R., RYBAKOWSKI, J. K., & Versiani, M. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200208000-00010 · Cited by 56
Efficacy and Tolerability of Reboxetine Compared with Citalopram
Langworth, S., Bodlund, O., & Ågren, H. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000204138.20417.c3 · Cited by 45
The Promises and Pitfalls of Reboxetine
Page, M. E. (2003) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2003.tb00258.x · Cited by 40
Ferguson, J. M., MENDELS, J., & Schwartz, G. E. (2002) · International Clinical Psychopharmacology · doi:10.1097/00004850-200203000-00001 · Cited by 40
The Antidepressant Efficacy of Reboxetine in Patients with Severe Depression
Montgomery, S., Ferguson, J. M., & Schwartz, G. E. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200302000-00008 · Cited by 38
The human pharmacology of reboxetine
Szabadi, E., Bradshaw, C. M., Boston, P. F., & Langley, R. W. (1998) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/(sici)1099-1077(199802)13:1+<s29::aid-hup980>3.0.co;2-d · Cited by 32
Reboxetine: A Norepinephrine Selective Reuptake Pump Inhibitor
Preskorn, S. (2004) · Journal of Psychiatric Practice · doi:10.1097/00131746-200401000-00006 · Cited by 27
Chuluunkhuu, G., Nakahara, N., Yanagisawa, S., & Kamae, I. (2008) · PubMed · doi:10.24546/81000771 · Cited by 16
Cited by
Sterne, J. A. C., Sutton, A. J., Ioannidis, J. P. A., Terrin, N., Jones, D. R., Lau, J., Carpenter, J., Rucker, G., Harbord, R. M., Schmid, C. H., et al. (2011) · BMJ · doi:10.1136/bmj.d4002 · Cited by 7,709
Statistical tests, P values, confidence intervals, and power: a guide to misinterpretations
Greenland, S., Senn, S. J., Rothman, K. J., Carlin, J. B., Poole, C., Goodman, S. N., & Altman, D. G. (2016) · European Journal of Epidemiology · doi:10.1007/s10654-016-0149-3 · Cited by 3,200
Increasing value and reducing waste: addressing inaccessible research
Chan, A.-W., Song, F., Vickers, A., Jefferson, T., Dickersin, K., Gøtzsche, P. C., Krumholz, H. M., Ghersi, D., & van der Worp, H. B. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62296-5 · Cited by 887
Shi, L., & Lin, L. (2019) · Medicine · doi:10.1097/md.0000000000015987 · Cited by 818
Cleare, A., Pariante, C., Young, A., Anderson, I., Christmas, D., Cowen, P., Dickens, C., Ferrier, I., Geddes, J., Gilbody, S., et al. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115581093 · Cited by 759
Metadata
- Authors
- Eyding, D., Lelgemann, M., Grouven, U., Harter, M., Kromp, M., Kaiser, T., Kerekes, M. F., Gerken, M., & Wieseler, B.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2010-10-12
- Volume
- 341
- Issue
- oct12 1
- Pages
- c4737-c4737
- ISSN
- 0007-1447 (ISSN-L)
- 0959-8138
- 1468-5833
- OpenAlex
- W2126194308
- Cited by
- 588
- References
- 45
- FWCI
- 5.40
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.